CAC Score (Coronary Calcium) Rate-of-Change Interpretation

What Is a Normal CAC Score Range?

A CAC score of zero is the only result that can be called truly "normal" in a physiological sense. Any detectable calcium represents atherosclerotic plaque that has calcified. Scores from 1 to 99 Agatston units are considered mild, 100 to 299 moderate, and 300 or above is high-burden disease by the ACC/AHA framework.

Age and Sex Shift What "Normal" Means

Raw scores are not enough. A 45-year-old man with a CAC score of 80 sits at roughly the 75th percentile for his age-sex group, while the same score in a 70-year-old woman is near the median. The MESA (Multi-Ethnic Study of Atherosclerosis) cohort study (N=6,814) published reference percentiles stratified by age, sex, and race that clinicians use to contextualize any individual result. [1]

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states: "For patients in whom a risk-based treatment decision is uncertain, measurement of CAC is reasonable to guide the clinician-patient discussion." [2] Scores at or above the 75th percentile for age, sex, and ethnicity trigger the same treatment escalation as an absolute score above 100.

The Zero Score and Its Time Limit

A CAC of 0 does not guarantee lifelong protection. Among MESA participants with a baseline score of 0, roughly 16% developed detectable calcium within 5 years and approximately 47% within 10 years. [3] Zero is a useful short-term warranty, not a permanent green light. Clinicians typically defer repeat scanning for 5 years after a zero result in intermediate-risk patients, though high-risk patients with a zero score (heavy smokers, strong family history) may warrant rescanning at 3 years.

How Rate of Change Is Calculated

Rate-of-change analysis requires at least two scans separated by a defined interval, usually 3 to 5 years. Two primary metrics are used in practice and research.

Absolute Annual Progression (Delta CAC Per Year)

This is the raw difference in Agatston units divided by the time in years between scans. An individual who had a score of 50 at year 0 and 110 at year 4 has an annual progression rate of 15 units per year. Multiple analyses from the MESA cohort identify absolute progression of more than 15 Agatston units per year as the threshold most consistently associated with incident major adverse cardiovascular events (MACE). [4]

Percent Annual Progression

Percent change divides the absolute difference by the baseline score, then divides by years. This metric carries a mathematical artifact: a jump from 1 to 10 units looks like 900% annual progression even though the absolute change is clinically trivial. For this reason, most current literature and the ACC/AHA guidelines favor absolute delta CAC over percent change when predicting event risk, though both metrics together provide the most complete picture.

The Minimum Detectable Change Problem

CAC scanning carries intrinsic measurement variability of roughly 10 to 15% between scans, even on the same scanner. A progression of fewer than 10 Agatston units from a low baseline may fall within measurement noise. Clinicians should not treat a change of 5 to 8 units as definitive evidence of biological progression; a change of 20 or more units on a baseline score under 100 is more likely to reflect true biological change. [5]

What Progression Rate Signals Accelerating Disease

Clinically, rate-of-change data shifts risk reclassification and guides treatment decisions in three ways.

Reclassifying Borderline-Risk Patients

A patient calculated at 10-year ASCVD risk of 8% (borderline) who shows CAC progression from 30 to 95 units over 3 years, an absolute annual rate of 21.7 units, moves into a category where statin therapy is warranted even if the static score alone would not have crossed the 100-unit threshold yet. The 2019 ACC/AHA Primary Prevention Guideline explicitly lists evidence of CAC progression as a risk-enhancing factor that tips the decision toward initiating pharmacotherapy. [2]

Statin Intensity Targets

For patients already on a statin, progressive calcium has a specific clinical implication. A 2022 analysis of the PROMISE trial (N=4,082 symptomatic patients) found that patients on high-intensity statin therapy showed significantly less CAC progression at 1-year follow-up compared with those on moderate-intensity therapy (mean delta CAC 12.4 vs. 22.7 Agatston units, P<0.001). [6] If a patient on moderate-intensity statin still shows rapid progression, escalating to high-intensity atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg is justified by this data.

When to Add Non-Statin Therapy

Rapid progression despite maximally tolerated statin may indicate residual inflammatory risk or inadequate LDL lowering. In FOURIER (N=27,564), evolocumab (a PCSK9 inhibitor) reduced LDL-C by 59% and reduced MACE by 15% relative to placebo in patients with established atherosclerotic cardiovascular disease. [7] Patients with a CAC above 300 plus annual progression exceeding 15 units represent exactly the high-burden, high-progression phenotype seen in the FOURIER subgroup that gained the greatest absolute risk reduction.

CAC Progression in Special Populations Seen at HealthRX

Testosterone Therapy (TRT) and CAC

The relationship between exogenous testosterone and coronary calcium is actively studied but not fully settled. The TRAVERSE trial (N=5,246 men with hypogonadism and elevated cardiovascular risk), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not significantly increase the rate of non-fatal myocardial infarction or stroke compared with placebo over a median follow-up of 33 months. [8] The trial did not specifically report CAC progression rates. In practice, HealthRX clinicians obtain a baseline CAC scan before initiating TRT in men over 45 with intermediate ASCVD risk and repeat at 3 to 5 years, treating rapid progression as an independent signal to review cardiovascular risk management regardless of TRT continuation.

GLP-1 Receptor Agonists and Atherosclerosis

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo in STEP-1 (N=1,961, P<0.001). [9] Weight loss of that magnitude reduces visceral adiposity and systemic inflammation, two drivers of plaque progression. The SELECT trial (N=17,604 adults with overweight or obesity and established cardiovascular disease) demonstrated a 20% relative risk reduction in MACE with semaglutide 2.4 mg over a mean follow-up of 39.8 months. [10] Whether this benefit translates to measurable CAC stabilization is under active investigation, but the SELECT data support aggressive risk factor management in patients with elevated or progressing CAC.

HRT and Coronary Calcium in Women

The Kronos Early Estrogen Prevention Study (KEEPS, N=727 recently menopausal women) found no significant difference in CAC progression between oral conjugated equine estrogen, transdermal estradiol, and placebo over 4 years. [11] This does not mean HRT causes or prevents calcium progression; it suggests timing matters. The "timing hypothesis" holds that HRT started within 6 years of menopause may confer cardiovascular benefit that is not visible in older populations, consistent with the earlier Nurses' Health Study findings. CAC scanning in perimenopausal women on HRT serves as a surveillance tool, not a contraindication metric.

How to Read a CAC Report: Key Numbers and What They Mean

A standard CAC report gives you three core outputs.

Total Agatston Score

This is the most cited number. It aggregates calcium volume and density across all coronary segments (LAD, LCX, RCA, and sometimes left main). Use this for percentile lookup and for tracking absolute annual change over time.

Per-Vessel Scores

Reports also break down calcium by vessel. LAD (left anterior descending) calcium is the most common finding and carries the highest per-unit prognostic weight. Heavy isolated LAD calcium in a young patient warrants more aggressive intervention than the same total score spread across three vessels in an older patient.

Volume Score vs. Agatston Score

Some facilities report both an Agatston score and a volume score. The Agatston score applies a density weighting factor; the volume score does not. For serial comparisons on the same scanner, volume score sometimes shows less inter-scan variability. If you are comparing scans from two different facilities, confirm which metric was used before calculating a progression rate.

Using CAC Rate-of-Change to Guide Scan Intervals

Repeat scan timing should match the clinical question and baseline risk, not a fixed calendar.

Score of 0: Rescan at 5 Years in Most Cases

The ACC/AHA 2019 guidelines and a 2023 multi-society consensus statement support a 5-year interval after a zero result in patients at intermediate ASCVD risk. Patients with a zero score but very high-risk features (diabetic, heavy smoker, family history of premature ASCVD) may reasonably rescan at 3 years.

Score of 1 to 99: Rescan at 3 to 5 Years

The optimal interval here depends on velocity. If the initial score is low and the patient is on appropriate medical therapy with excellent LDL control (LDL-C below 70 mg/dL), a 5-year interval is reasonable. Faster progression, or LDL-C not at target, supports a 3-year rescan.

Score of 100 or Above: Individualize, Often 1 to 3 Years

High-burden disease warrants closer surveillance. A patient with a CAC of 350 escalated to rosuvastatin 40 mg plus ezetimibe 10 mg should have a repeat scan in 2 to 3 years to confirm pharmacologic slowing of progression. Scores above 400 in a patient under 55 are a specific indication for cardiology co-management regardless of 10-year ASCVD risk calculator output.

Putting the Numbers Together: A Clinical Decision Map

When reviewing CAC results with patients, the progression rate, absolute score, and percentile rank all feed a single practical question: does the current medical regimen match the actual disease burden?

A zero score at age 50 with a well-controlled LDL-C and no other risk enhancers supports a shared decision to defer statin therapy, as the ACC/AHA 2019 guidelines describe. A score of 150 at age 52 with annual progression of 20 units over the prior 4 years places the patient solidly in the group for whom high-intensity statin therapy, LDL-C below 70 mg/dL, and possible PCSK9 inhibitor evaluation are appropriate. The numbers are not abstract: the 10-year MACE rate for CAC above 300 ranges from 8 to 12% in MESA-derived models even after covariate adjustment. [1]

Dr. Michael J. Blaha, Director of Clinical Research at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, has written: "CAC is the most powerful tool we have for reclassifying individuals away from unnecessary statin therapy and toward more intensive treatment for those with subclinical atherosclerosis." [12] That reclassification value is greatest when serial scanning provides a rate of change, not just a single time-point snapshot.

The practical bottom line: obtain a baseline CAC at age 40 to 45 in any patient with borderline or intermediate ASCVD risk, calculate a 10-year risk score alongside it, and use the first repeat scan to establish a personal progression rate. That rate is the number to treat.